SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment o… Read more
SQZ Biotechnologies Company (SQZB) - Net Assets
Latest net assets as of September 2023: $1.88 Million USD
Based on the latest financial reports, SQZ Biotechnologies Company (SQZB) has net assets worth $1.88 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.79 Million) and total liabilities ($27.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.88 Million |
| % of Total Assets | 6.31% |
| Annual Growth Rate | -2.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 63.13 |
SQZ Biotechnologies Company - Net Assets Trend (2018–2022)
This chart illustrates how SQZ Biotechnologies Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SQZ Biotechnologies Company (2018–2022)
The table below shows the annual net assets of SQZ Biotechnologies Company from 2018 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $57.15 Million | -53.90% |
| 2021-12-31 | $123.98 Million | -2.53% |
| 2020-12-31 | $127.20 Million | +117.09% |
| 2019-12-31 | $58.59 Million | -6.79% |
| 2018-12-31 | $62.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SQZ Biotechnologies Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23092800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | 0.05% |
| Other Components | $332.09 Million | 581.11% |
| Total Equity | $57.15 Million | 100.00% |
SQZ Biotechnologies Company Competitors by Market Cap
The table below lists competitors of SQZ Biotechnologies Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arqit Quantum Inc. Warrants
NASDAQ:ARQQW
|
$707.87K |
|
Equity Story Group Ltd
AU:EQS
|
$708.17K |
|
Rover Metals Corp
OTCQB:ROVMF
|
$708.42K |
|
WAYSIDE TECH GRP
MU:PYA
|
$708.49K |
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
$707.44K |
|
Hui Srl
VI:HUI
|
$706.84K |
|
KELLOGG - Dusseldorf Stock Exchang
DU:KEL
|
$706.50K |
|
ESTEE LAUDER-A - Dusseldorf Stock Exchang
DU:ELAA
|
$706.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SQZ Biotechnologies Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 123,976,000 to 57,148,000, a change of -66,828,000 (-53.9%).
- Net loss of 79,464,000 reduced equity.
- New share issuances of 4,067,000 increased equity.
- Other factors increased equity by 8,569,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-79.46 Million | -139.05% |
| Share Issuances | $4.07 Million | +7.12% |
| Other Changes | $8.57 Million | +14.99% |
| Total Change | $- | -53.90% |
Book Value vs Market Value Analysis
This analysis compares SQZ Biotechnologies Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $2.55 | $0.03 | x |
| 2019-12-31 | $2.38 | $0.03 | x |
| 2020-12-31 | $5.13 | $0.03 | x |
| 2021-12-31 | $4.50 | $0.03 | x |
| 2022-12-31 | $1.98 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SQZ Biotechnologies Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -139.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -377.88%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.88x
- Recent ROE (-139.05%) is below the historical average (-64.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -32.19% | -159.71% | 0.11x | 1.84x | $-26.52 Million |
| 2019 | -54.96% | -160.14% | 0.13x | 2.60x | $-38.06 Million |
| 2020 | -39.72% | -240.60% | 0.09x | 1.82x | $-63.24 Million |
| 2021 | -55.45% | -253.68% | 0.12x | 1.82x | $-81.14 Million |
| 2022 | -139.05% | -377.88% | 0.20x | 1.88x | $-85.18 Million |
Industry Comparison
This section compares SQZ Biotechnologies Company's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SQZ Biotechnologies Company (SQZB) | $1.88 Million | -32.19% | 14.84x | $707.79K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |